Skip to main content
EU OKs Cerenovus' blood flow diverter

European regulators have granted Johnson & Johnson company Cerenovus CE mark approval for its Bravo blood flow diverter for use in the treatment of complex aneurysm. The device is indicated for diverting blood flow from the aneurysm site to treat patients with intracranial aneurysms.

Full Story: